Meletios-Athanasios (Thanos) C. Dimopoulos
Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, and a leading global expert in multiple myeloma and plasma cell dyscrasias. Former Rector of NKUA.
1
APPEARANCES
1
PODCASTS
Aug 20, 2026
5:15
And if we focus on the Thelmots, Professor Dimopoulos, so what are Thelmot agents and what is the mechanism of action and how these Thelmot agents differentiate from the classical immunomodulatory drugs that we've been using for the last 20 or 25 years in myeloma?
5:41
I agree with you that despite the progress that we have made, we still need agents that have a different mechanism of action.
5:52
Ibergamide and mesigdomide are the two cell modes that are in clinical development.
5:59
They bind to cereblon within the CR-L4 ligase complex.
6:05
And this binding is much more effective than the one that we're seeing with image.
16 MINS LATER
21:47
I don't know if you visualize any potential barrier to the near future Thelmots agents integration into the treatment landscape for patients with multiple myeloma.